Meanwhile, orforgliprons oral GLP-1 format may finally unlock mass adoption by removing injection-related barriers, while Survodutide, CT-388, and Pemvidutide demonstrate that dual and triple agonists, with novel combinations of GLP-1, glucagon, and GIP, can outperform monotherapies in both efficacy and metabolic breadth
A recent study has demonstrated that 6-diazo-5-oxo-l-norleucine (DON) facilitates metabolic adaptations in tumor CD8 T cells, exhibiting promising clinical efficacy in ongoing trials [102]
Urbina J et al
The drugs more common side effects tend to go away within a few weeks as your body adjusts to the medication
Deciphering the iron side of stroke: neurodegeneration at the crossroads between iron dyshomeostasis, excitotoxicity, and ferroptosis